Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Vogel

Showing results (391-400 of 456) with videos related to

Pageof 46
Sort By:
Multiple Sclerosis and Related Disorders|March 7, 2026
Effects of disease modifying therapy on cognitive proficiency in pediatric-onset multiple sclerosis (POMS)Ashley M Whitaker, Emily Zhou, Brooke K Iwamoto, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 10, 2024
Therapeutic targeting of full-length interleukin-33 protein levels with cell-permeable decoy peptides attenuates fibrosis in the bleomycin model in vivoSergei P Atamas, Virginia K Lockatell, Nevins W Todd, et al.
Journal of Psychosomatic Research|November 4, 2015
Circadian rhythm disruption as a link between Attention-Deficit/Hyperactivity Disorder and obesity?Suzan W N Vogel, Denise Bijlenga, Marjolein Tanke, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signalingPrasad Rallabhandi, Jessica Bell, Marina S Boukhvalova, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young childrenAgnes A Awomoyi, Prasad Rallabhandi, Toni I Pollin, et al.
Innate Immunity|March 4, 2025
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infectionKari Ann Shirey, Alessio Romerio, Mohammed Monsoor Shaik, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2002
Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway componentsMarina A Dobrovolskaia, Andrei E Medvedev, Karen E Thomas, et al.
Cell Reports|June 23, 2015
A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of InfluenzaWenji Piao, Kari Ann Shirey, Lisa W Ru, et al.
Scientific Reports|January 21, 2017
TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infectionLaure Perrin-Cocon, Anne Aublin-Gex, Stefania E Sestito, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 1994
Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor familyC Bovolenta, P H Driggers, M S Marks, et al.
Pageof 46

Showing results (391-400 of 456) with videos related to

Sort By:
Pageof 46
Multiple Sclerosis and Related Disorders|March 7, 2026
Effects of disease modifying therapy on cognitive proficiency in pediatric-onset multiple sclerosis (POMS)Ashley M Whitaker, Emily Zhou, Brooke K Iwamoto, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 10, 2024
Therapeutic targeting of full-length interleukin-33 protein levels with cell-permeable decoy peptides attenuates fibrosis in the bleomycin model in vivoSergei P Atamas, Virginia K Lockatell, Nevins W Todd, et al.
Journal of Psychosomatic Research|November 4, 2015
Circadian rhythm disruption as a link between Attention-Deficit/Hyperactivity Disorder and obesity?Suzan W N Vogel, Denise Bijlenga, Marjolein Tanke, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signalingPrasad Rallabhandi, Jessica Bell, Marina S Boukhvalova, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young childrenAgnes A Awomoyi, Prasad Rallabhandi, Toni I Pollin, et al.
Innate Immunity|March 4, 2025
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infectionKari Ann Shirey, Alessio Romerio, Mohammed Monsoor Shaik, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2002
Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway componentsMarina A Dobrovolskaia, Andrei E Medvedev, Karen E Thomas, et al.
Cell Reports|June 23, 2015
A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of InfluenzaWenji Piao, Kari Ann Shirey, Lisa W Ru, et al.
Scientific Reports|January 21, 2017
TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infectionLaure Perrin-Cocon, Anne Aublin-Gex, Stefania E Sestito, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 1994
Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor familyC Bovolenta, P H Driggers, M S Marks, et al.
Pageof 46